Activating KRAS mutations are found in more than 90% of pancreatic adenocarcinomas and are highly associated with disease progression due to the activation of several effector pathways that induce cell proliferation, survival, invasion, and metabolic alterations [3-5]. Here, KRAS is linked to pancreatic adenocarcinoma.